HealthlineNew Breast Density Treatment May Have Fewer Side Effects, Lower Cancer Risk

⚠️ Small Study / Early Comparative Evidence
The KARISMA Endoxifen trial, published in the Journal of the National Cancer Institute, randomized 240 premenopausal women ages 40–55 to placebo, 1 mg, or 2 mg daily (Z)-endoxifen for six months. Mammographic breast density served as the proxy endpoint for breast cancer risk reduction.

Clinical Considerations

• 1 mg endoxifen reduced breast density by 19.3% and 2 mg by 26.5% versus essentially no change with placebo — comparable to reductions previously reported with standard 20 mg tamoxifen.
• Breast density reduction plateaued at plasma concentrations of 3–4 ng/mL, suggesting higher doses may not add benefit.
• The 1 mg dose showed better tolerability with fewer treatment discontinuations and no worsening of vasomotor symptoms versus placebo.
• This is a proof-of-concept trial using breast density as a surrogate; direct breast cancer incidence reduction has not been established.

Practice Applications

• Recognize mammographic breast density as a modifiable risk marker, not a confirmed clinical endpoint.
• Interpret findings as hypothesis-generating pending larger, longer trials with cancer incidence outcomes.
• Consider tolerability barriers as a major driver of nonadherence in current tamoxifen prevention regimens.
• Monitor ongoing endoxifen development for potential expansion of preventive options in patients intolerant of standard SERMs.